



1 September 2017

Announcements
National Stock Exchange of Australia
PO Box 283
NEWCASTLE NSW 2300

Market Announcement – Unconditional Registration for ESVCLP Fund

Today iQX Limited (iQX) announced its wholly owned subsidiary iQX Investment Services Pty Ltd (Fund Manager) received notification from the Australian Government Department of Industry, Innovation and Science for unconditional registration of the iQ Series 8 Life Science Fund (Global) ESVCLP LP (Series 8) as an early stage venture capital limited partnership (ESVCLP).

Entirely funded by private investment, the iQ Series 8 Fund is completely independent and not backed by Government funding. With the fund currently capped at AUD 100 million, this is a large capital commitment to be strategically invested in Australian biotechnology opportunities.

“We are thrilled to be able to continue to fund life science innovation, focused on delivering the medicines of tomorrow. The iQ Series 8 Fund is a tax effective investment generating returns post a 12 month investment period”, said Dr George Syrmalis, Founder and CEO.

The iQ Series 8 Fund will leverage an extensive life science network allowing access to deal flows, ranging from universities’ drug discovery and drug development projects and life science enterprise incubators in Australia and abroad, through to corporatised assets in the drug and technology development life cycle.

“The advent of genomic and molecular medicine is the biggest investment theme of our lifetime. The industry is innovative and fast paced, essentially a competition to commercialise intellectual property. With seven billion humans on the planet, the life sciences industry is assured to sustain growth of demand, hence it creates reasons to be an overweight sector for investors.” Dr Syrmalis continued.

Beyond the typical qualifications and industry-specific experience, the Fund management team are experts in life sciences, corporate advisory, investment banking, private equity, venture capital and business.

“When investing in biotech it is paramount to have a pragmatic investment doctrine. It is imperative that the benefits of the innovation the investee enterprises are pursuing need to accrue to the companies, and by extension to the shareholders, not just the potential customers. We draw a distinction between investable themes and those that sound good but deliver little to investors. We only invest in companies with a clear competitive advantage and our investment doctrine stems from the triptych : Science, People, Financials.” Dr Syrmalis stated.

A handwritten signature in black ink, appearing to read 'KOS', with a horizontal line underneath the letters.

Kos Dimitriou
Chairman

IQX Ltd is a specialist life science investment organisation

Sydney: Level 3, 222 Clarence Street, Sydney, NSW 2000, Australia •Phone: +61 2 8239 5400

New York: 400 Madison Avenue, Suite 10A, New York City NY10017 USA •Phone: +1 212 433 2630

London: 20 Broadwick Street, London, W1F-8HT, UK • Phone: +44(0)2077121508